Treatment Considerations for Transplant-Ineligible Multiple Myeloma

Radowan A. Elnair, Sarah A. Holstein

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


While significant advances have been made in the treatment of multiple myeloma, the management of the transplantineligible (TI) patient population remains challenging. The individuals enrolled in clinical trials for newly diagnosed TI patients, or those with no planned transplant, may not always be reflective of real-world patients, with respect to age, comorbidities, or frailty status. Likewise, results obtained from randomized relapsed/refractory studies also may not be applicable to this generally older and frailer patient population. In this review, we discuss assessment of frailty and focus on treatment options in both the newly diagnosed and relapsed/refractory settings for TI patients. We describe the patient-specific considerations that factor into treatment decisions as well as provide some guidance about management.

Original languageEnglish (US)
Pages (from-to)170-189
Number of pages20
JournalONCOLOGY (United States)
Issue number4
StatePublished - Apr 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment Considerations for Transplant-Ineligible Multiple Myeloma'. Together they form a unique fingerprint.

Cite this